NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN) Stock Rises Despite Deepening Losses And Cash Burn
Viridian Therapeutics stock climbed about 5% today, yet the headline from this quarter is not a sudden profit swing. The story is a widening loss set against a biotech pipeline that still sits in heavy investment mode. In Q2, Viridian reported basic earnings per share of a loss of US$1.18 and a net loss of about US$127.1 million on revenue of just US$0.3 million.
For a development stage biotech this kind of margin squeeze can either be growing pains or a red flag. The following sections...